Adjuvant treatment in operable breast cancer

Research output: Contribution to journalArticle

Abstract

The object of Ludwig III was to assess adjuvant therapy after total mastectomy and axillary clearance in postmenopausal women with breast cancer and axillary node metastases. Chemo-endocrine therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone and tamoxifen: CMFp + T) was compared with endocrine therapy (prednisone and tamoxifen: p + T) and with no adjuvant treatment in 463 evaluable patients aged 65 years or less. Treatment results are available (Ludwig Breast Cancer Study Group, Lancet i (1984) 1256-1260). Nodal status and receptor content of the primary were found to have prognostic value, while tumor size did not.

Original languageEnglish
Pages (from-to)1155-1160
Number of pages6
JournalJournal of Steroid Biochemistry
Volume23
Issue number6 PART 2
DOIs
Publication statusPublished - 1985

Fingerprint

Tamoxifen
Prednisone
Breast Neoplasms
Methotrexate
Fluorouracil
Cyclophosphamide
Tumors
Simple Mastectomy
Therapeutics
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Adjuvant treatment in operable breast cancer. / Goldhirsch, A.

In: Journal of Steroid Biochemistry, Vol. 23, No. 6 PART 2, 1985, p. 1155-1160.

Research output: Contribution to journalArticle

@article{a7b7e2b253cc4ba88fe9574d3a66458a,
title = "Adjuvant treatment in operable breast cancer",
abstract = "The object of Ludwig III was to assess adjuvant therapy after total mastectomy and axillary clearance in postmenopausal women with breast cancer and axillary node metastases. Chemo-endocrine therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone and tamoxifen: CMFp + T) was compared with endocrine therapy (prednisone and tamoxifen: p + T) and with no adjuvant treatment in 463 evaluable patients aged 65 years or less. Treatment results are available (Ludwig Breast Cancer Study Group, Lancet i (1984) 1256-1260). Nodal status and receptor content of the primary were found to have prognostic value, while tumor size did not.",
author = "A. Goldhirsch",
year = "1985",
doi = "10.1016/0022-4731(85)90036-6",
language = "English",
volume = "23",
pages = "1155--1160",
journal = "Journal of Steroid Biochemistry",
issn = "0022-4731",
publisher = "Pergamon Press Ltd.",
number = "6 PART 2",

}

TY - JOUR

T1 - Adjuvant treatment in operable breast cancer

AU - Goldhirsch, A.

PY - 1985

Y1 - 1985

N2 - The object of Ludwig III was to assess adjuvant therapy after total mastectomy and axillary clearance in postmenopausal women with breast cancer and axillary node metastases. Chemo-endocrine therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone and tamoxifen: CMFp + T) was compared with endocrine therapy (prednisone and tamoxifen: p + T) and with no adjuvant treatment in 463 evaluable patients aged 65 years or less. Treatment results are available (Ludwig Breast Cancer Study Group, Lancet i (1984) 1256-1260). Nodal status and receptor content of the primary were found to have prognostic value, while tumor size did not.

AB - The object of Ludwig III was to assess adjuvant therapy after total mastectomy and axillary clearance in postmenopausal women with breast cancer and axillary node metastases. Chemo-endocrine therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone and tamoxifen: CMFp + T) was compared with endocrine therapy (prednisone and tamoxifen: p + T) and with no adjuvant treatment in 463 evaluable patients aged 65 years or less. Treatment results are available (Ludwig Breast Cancer Study Group, Lancet i (1984) 1256-1260). Nodal status and receptor content of the primary were found to have prognostic value, while tumor size did not.

UR - http://www.scopus.com/inward/record.url?scp=0022310058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022310058&partnerID=8YFLogxK

U2 - 10.1016/0022-4731(85)90036-6

DO - 10.1016/0022-4731(85)90036-6

M3 - Article

C2 - 3912622

AN - SCOPUS:0022310058

VL - 23

SP - 1155

EP - 1160

JO - Journal of Steroid Biochemistry

JF - Journal of Steroid Biochemistry

SN - 0022-4731

IS - 6 PART 2

ER -